The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Cellmid (CDY) has received import permits allowing the sale of its Jo-Ju and Lexilis-branded shampoos in mainland China
  • Based in Sydney, Cellmid is a health and beauty company leveraging innovative anti-aging technologies
  • The permits, issued by the Chinese National Medical Products Administration, are essential for the sale of fully finished products in China
  • The documents allow CDY to progress its 10-year distribution deal with Ourui Health Management
  • Cellmid shares are up 2.94 per cent, trading at 7 cents each

Cellmid (CDY) has received import permits allowing the sale of its Jo-Ju and Lexilis-branded shampoos in mainland China.

Based in Sydney, Cellmid is a health and beauty business leveraging innovative anti-aging technologies.

The permits, issued by the Chinese National Medical Products Administration (NMPA), are essential for the sale of fully finished products in China.

Cellmid says the receipt of the documents is a key milestone in implementing its 10-year distribution agreement signed with Ourui Health Management in December last year.

The permits do not have an expiry date and will remain valid subject to Cellmid’s compliance with NMPA’s annual reporting requirements.

On the market this afternoon, Cellmid shares are up 2.94 per cent, trading at 7 cents at 1:17 pm AEST.

CDY by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…